Use Code ONLINE20 to Save 20% On Global Market Reports – Gain Access to Trusted Market Data, Growth Indicators, and Industry Analytics
What Is the Growth Potential of the Androgen Deprivation Therapy Market Size Over 2025-2034?
The androgen deprivation therapy market size has grown strongly in recent years. It will grow from $7.81 billion in 2024 to $8.31 billion in 2025 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to rising incidence of prostate cancer globally, increasing aging male population, high recurrence rate of prostate cancer, improved survival rates encouraging long-term treatment, and growing awareness about early prostate cancer screening.
The androgen deprivation therapy market size is expected to see strong growth in the next few years. It will grow to $10.49 billion in 2029 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to increasing adoption of combination therapies in oncology, rising prevalence of hormone-sensitive cancers, high rates of localized and advanced prostate cancer diagnosis, expanding use of ADT in non-oncological hormonal conditions, and increasing patient preference for non-invasive treatment options. Major trends in the forecast period include advancements in depot formulations and delivery methods, development of oral ADT drugs, emergence of long-acting ADT injectables, introduction of novel androgen receptor inhibitors, and technological innovations in digital pathology and diagnostics.
Get your free report sample today:
What Are the Leading Drivers Behind the Growth of the Androgen Deprivation Therapy Market?
The increasing incidence of prostate cancer is expected to fuel the growth of the androgen deprivation therapy market in the coming years. Prostate cancer originates in the prostate gland, a part of the male reproductive system responsible for producing seminal fluid. Its incidence is climbing mainly due to longer life spans, as older age significantly raises the risk of developing the disease. Androgen deprivation therapy (ADT) is a primary treatment modality for prostate cancer, aimed at lowering androgen levels that drive tumor growth. It is frequently utilized in advanced or metastatic stages to delay disease progression. For instance, in January 2025, according to a report published by Prostate Cancer UK, a UK-based prostate cancer research, awareness, and support organization, in England, the number of prostate cancer diagnoses increased from 50,751 cases in 2022 to 55,033 cases in 2023, indicating a clear rise in annual incidence. Therefore, the increasing incidence of prostate cancer is driving the growth of the androgen deprivation therapy market.
Which Market Segment Offers the Most Significant Growth Opportunities in the Androgen Deprivation Therapy Market?
The androgen deprivation therapy market covered in this report is segmented –
1) By Type: Medicine, Surgery, Other Types
2) By Route Of Administration: Injectable, Oral
3) By Patient Demographics: Men Aged 40-60, Men Aged 61-75, Men Above 75
4) By Application: Prostate Cancer, Other Applications
5) By End-User: Hospitals, Specialty Clinics, Other End-Users
Subsegments:
1) By Medicine: LHRH Agonists, LHRH Antagonists, Anti-Androgens, CYP17 Inhibitors, Steroidal Anti-Androgens, Non-Steroidal Anti-Androgens, Estrogen-Based Therapies, Combination Therapies
2) By Surgery: Bilateral Orchiectomy, Subcapsular Orchiectomy, Simple Orchiectomy
3) By Other Types: Radiopharmaceutical Therapy, Gene Therapy, Immunotherapy, Targeted Therapy, Cryotherapy, High-Intensity Focused Ultrasound (HIFU
Which Emerging Trends Are Shaping the Future of the Androgen Deprivation Therapy Market?
Major companies operating in the androgen deprivation therapy market are focusing on developing advanced solutions, such as combination therapies, to improve treatment outcomes in advanced prostate cancer. Combination therapy involves using more than one type of treatment, such as hormone therapy plus chemotherapy, to enhance therapeutic effectiveness and delay disease progression. For instance, in August 2022, Bayer AG, a Germany-based life sciences company, received U.S. Food and Drug Administration approval for the additional indication of darolutamide in combination with docetaxel for treating metastatic hormone-sensitive prostate cancer (mHSPC). The newly approved combination therapy aims to enhance survival outcomes and delay disease advancement in individuals with metastatic hormone-sensitive prostate cancer (mHSPC), a condition where cancer has spread but still responds to hormone treatment. A standout element of this therapy is darolutamide, an oral medication that targets androgen receptors. Its unique molecular structure enables it to attach firmly to these receptors. By doing so, it effectively blocks their activity, helping to inhibit the development and spread of prostate cancer cells.
Who Are the Top Industry Players Driving the Androgen Deprivation Therapy Market Growth?
Major companies operating in the androgen deprivation therapy market are Pfizer Inc., Johnson & Johnson Services Inc., Merck & Co. Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Astellas Pharma Inc., Ipsen S.A., Dr. Reddy's Laboratories Ltd., Orion Corporation, Arvinas Inc., Ferring Pharmaceuticals SA, Tolmar Pharmaceuticals Inc., Besins Healthcare S.A., Veru Inc., Kintor Pharmaceutical Limited, Foresee Pharmaceuticals Co. Ltd., Verity Pharmaceuticals Inc., Lawley Pharmaceuticals Pty Ltd.
Get the detailed androgen deprivation therapy market report today
Which Regional Markets Offer the Most Promising Growth Opportunities for the Androgen Deprivation Therapy Market?
North America was the largest region in the androgen deprivation therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the androgen deprivation therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company: https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment